Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates Medical Dialogues Bureau30 Oct 2019 4:00 AMPfizer said it expects to earn between $2.94 per share and $3.00 per share, up from a prior estimate of $2.76 to $2.86. Analysts on average were...
Pfizer epilepsy drug Lyrica fails in phase III trial Medical Dialogues Bureau28 May 2019 3:30 AMNew Delhi: Pfizer Inc. recently announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5...
Vaccine and blood thinner help drive Pfizer to quarterly earnings beat Medical Dialogues Bureau1 May 2019 6:37 AMPfizer Inc on Tuesday reported a first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company...
Pfizer loses blockbuster Epilepsy drug patent fight in UK Supreme Court Medical Dialogues Bureau15 Nov 2018 6:12 AMThe expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut-price versions of Pfizer's medicine, which...
